Fluidigm Co. (NASDAQ:FLDM) Insider Buys $41,485.20 in Stock

Fluidigm Co. (NASDAQ:FLDM) insider Levin Capital Strategies, L.P. bought 7,240 shares of the company’s stock in a transaction dated Monday, April 2nd. The stock was purchased at an average price of $5.73 per share, with a total value of $41,485.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Levin Capital Strategies, L.P. also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Friday, March 23rd, Levin Capital Strategies, L.P. bought 7,720 shares of Fluidigm stock. The stock was purchased at an average price of $5.97 per share, with a total value of $46,088.40.
  • On Monday, March 26th, Levin Capital Strategies, L.P. bought 21,020 shares of Fluidigm stock. The stock was purchased at an average price of $5.83 per share, with a total value of $122,546.60.
  • On Thursday, March 8th, Levin Capital Strategies, L.P. bought 40,000 shares of Fluidigm stock. The stock was purchased at an average price of $6.48 per share, with a total value of $259,200.00.
  • On Monday, March 5th, Levin Capital Strategies, L.P. bought 7,500 shares of Fluidigm stock. The stock was purchased at an average price of $6.17 per share, with a total value of $46,275.00.
  • On Friday, March 2nd, Levin Capital Strategies, L.P. bought 250,355 shares of Fluidigm stock. The stock was purchased at an average price of $6.25 per share, with a total value of $1,564,718.75.
  • On Wednesday, February 28th, Levin Capital Strategies, L.P. bought 13,950 shares of Fluidigm stock. The stock was purchased at an average price of $6.82 per share, with a total value of $95,139.00.
  • On Thursday, February 15th, Levin Capital Strategies, L.P. acquired 10,000 shares of Fluidigm stock. The shares were bought at an average price of $7.86 per share, with a total value of $78,600.00.
  • On Wednesday, February 7th, Levin Capital Strategies, L.P. acquired 53,610 shares of Fluidigm stock. The shares were bought at an average price of $5.73 per share, with a total value of $307,185.30.
  • On Monday, February 5th, Levin Capital Strategies, L.P. acquired 50,987 shares of Fluidigm stock. The shares were bought at an average price of $5.96 per share, with a total value of $303,882.52.
  • On Thursday, February 1st, Levin Capital Strategies, L.P. acquired 152,891 shares of Fluidigm stock. The shares were bought at an average price of $6.18 per share, with a total value of $944,866.38.

FLDM traded down $0.03 during trading on Thursday, reaching $6.10. 3,966 shares of the company’s stock were exchanged, compared to its average volume of 197,421. Fluidigm Co. has a one year low of $2.52 and a one year high of $8.38. The company has a debt-to-equity ratio of 6.31, a current ratio of 2.83 and a quick ratio of 2.38. The firm has a market capitalization of $241.80, a price-to-earnings ratio of -5.15 and a beta of 2.99.

Fluidigm (NASDAQ:FLDM) last posted its earnings results on Thursday, February 8th. The medical research company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). Fluidigm had a negative return on equity of 118.56% and a negative net margin of 59.38%. The business had revenue of $27.75 million for the quarter, compared to the consensus estimate of $27.14 million. During the same period in the previous year, the firm earned ($0.32) earnings per share. The company’s revenue was up 10.6% compared to the same quarter last year. equities research analysts predict that Fluidigm Co. will post -0.93 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of FLDM. Dimensional Fund Advisors LP grew its holdings in Fluidigm by 9.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 136,003 shares of the medical research company’s stock worth $549,000 after acquiring an additional 11,557 shares during the last quarter. State Street Corp grew its holdings in Fluidigm by 6.2% during the 2nd quarter. State Street Corp now owns 499,524 shares of the medical research company’s stock worth $2,017,000 after acquiring an additional 29,110 shares during the last quarter. Sei Investments Co. grew its holdings in Fluidigm by 221.7% during the 3rd quarter. Sei Investments Co. now owns 21,668 shares of the medical research company’s stock worth $109,000 after acquiring an additional 14,932 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Fluidigm by 70.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 370,427 shares of the medical research company’s stock worth $1,867,000 after acquiring an additional 152,588 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Fluidigm during the 3rd quarter worth approximately $123,000. 94.64% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently issued reports on FLDM. BidaskClub cut shares of Fluidigm from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 24th. Piper Jaffray reiterated a “hold” rating and set a $6.10 price objective on shares of Fluidigm in a research report on Thursday, February 8th. Finally, ValuEngine cut shares of Fluidigm from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/19/levin-capital-strategies-l-p-acquires-7240-shares-of-fluidigm-co-fldm-stock.html.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Insider Buying and Selling by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply